Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency"

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 1, 2012, Pages 55-73

  Rupp, Heinz ^a   Rupp, Thomas P ^a,b   Alter, Peter ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Burgerhospital Frankfurt am Main   (Germany)

Author keywords

Aortic constriction; Cardiac dilatation; Doca salt hypertension; Etomoxir; Fatty acids; Fenofibrate; Heart failure; Highly unsaturated fatty acids; Hypertrophy; Omega 3 acid ethyl esters

Indexed keywords

ACYL COENZYME A DESATURASE 1; ARACHIDONIC ACID; CARNITINE PALMITOYLTRANSFERASE I; DEOXYCORTICOSTERONE ACETATE; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PALMITOLEIC ACID; STEARIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FEMALE; HEART ATRIUM ENLARGEMENT; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL STRESS; HEART MUSCLE CONTRACTILITY; HEART RATE VARIABILITY; HEART VENTRICLE OVERLOAD; HIGHLY UNSATURATED FATTY ACID DEFICIENCY; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC TONE; WALL STRESS;

ANIMALS; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACID DESATURASES; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; LIVER; MALE; MIDDLE AGED; MYOCARDIUM; RATS; RATS, WISTAR; SODIUM CHLORIDE;

EID: 84855572994     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y11-101     Document Type: Article

References (69)

1. Albert, C.M., Campos, H., Stampfer, M.J., Ridker, P.M., Manson, J. E., Willett, W.C., and Ma, J. 2002. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346(15): 1113-1118. doi:10.1056/NEJMoa012918.
2. Alter, P., and Rupp, H. 2011. Letter by Alter and Rupp regarding article, "OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation, 124(1): e23, author reply e24-e25. doi:10.1161/CIRCULATIONAHA.110.013607.
3. Alter, P., Grimm, W., Vollrath, A., Czerny, F., and Maisch, B. 2006. Heart rate variability in patients with cardiac hypertrophy-relation to left ventricular mass and etiology. Am. Heart J. 151(4): 829-836. doi:10.1016/j.ahj.2005.06.016.
4. Alter, P., Rupp, H., Rominger, M.B., Vollrath, A., Czerny, F., Klose, K.J., and Maisch, B. 2007. Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy. Can. J. hysiol. Pharmacol. 85(8): 790-799. doi:10.1139/Y07-076.
5. Alter, P., Rupp, H., Rominger, M.B., Klose, K.J., and Maisch, B. 2008a. A new methodological approach to assess cardiac work by pressure-volume and stress-length relations in patients with aortic valve stenosis and dilated cardiomyopathy. Pflugers Arch. 455(4): 627-636. doi:10.1007/s00424-007-0323-2.
6. Alter, P., Rupp, H., Rominger, M.B., Vollrath, A., Czerny, F., Figiel, J.H., et al. 2008b. B-type natriuretic peptide and wall stress in dilated human heart. Mol. Cell. Biochem. 314(1-2): 179-191.doi:10.1007/s11010-008-9779-4.
7. Alter, P., Rupp, H., Rominger, M.B., Figiel, J.H., Renz, H., Klose, K. J., and Maisch, B. 2010. Association of hyperhomocysteinemia with left ventricular dilatation and mass in human heart. Clin. Chem. Lab. Med. 48(4): 555-560. doi:10.1515/CCLM.2010.102.
8. Ander, B.P., Dupasquier, C.M., Prociuk, M.A., and Pierce, G.N. 2003. Polyunsaturated fatty acids and their effects on cardiovascular disease. Exp. Clin. Cardiol. 8(4): 164-172.
9. Benedetto, U., Melina, G., di Bartolomeo, R., Angeloni, E., Sansone, D., Falaschi, G., et al. 2011. n-3 Polyunsaturated fatty acids after coronary artery bypass grafting. Ann. Thorac. Surg. 91(4): 1169-1175. doi:10.1016/j.athoracsur.2010.11.068.
10. Bianconi, L., Calo, L., Mennuni, M., Santini, L., Morosetti, P., Azzolini, P., et al. 2011. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace, 13(2): 174-181. doi:10.1093/europace/euq386.
11. Birkenfeld, A.L., Boschmann, M., Moro, C., Adams, F., Heusser, K., Franke, G., et al. 2005. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab. 90(6): 3622-3628. doi:10.1210/jc.2004-1953.
12. Brilla, C.G., Funck, R.C., and Rupp, H. 2000. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation, 102(12): 1388-1393.
13. Brilla, C.G., Rupp, H., and Maisch, B. 2003. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz, 28(8): 744-753. doi:10.1007/s00059-003-2524-6.
14. Calder, P.C. 2009. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie, 91(6): 791-795. doi:10.1016/j.biochi.2009.01.008.
15. CCAC (Canadian Council on Animal Care). 1993. Guideline to the care and use of experimental animals. Edited by E.D. Olfert, B. M. Cross, and A.A. McWilliamAvailable from www.ccac.ca/Documents/Standards/Guidelines/Experimental_Animals_Vol1.pdf.
16. Devereux, R.B., Alonso, D.R., Lutas, E.M., Gottlieb, G.J., Campo, E., Sachs, I., and Reichek, N. 1986. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57(6): 450-458. doi:10.1016/0002-9149(86) 90771-X.
17. Finzi, A.A., Latini, R., Barlera, S., Rossi, M.G., Ruggeri, A., Mezzani, A., et al. 2011. Effects of n-3 polyunsaturated fatty acidson malignant entricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am. Heart J. 161(2): 338-343. e1. doi:10.1016/j.ahj.2010.10.032.
18. Flowers, M.T., and Ntambi, J.M. 2009. Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochim. Biophys. Acta, 1791(2): 85-91.
19. Fruchart, J.C., and Duriez, P. 2006. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc), 42(1): 39-64. doi:10.1358/dot.2006.42.1.963528.
20. Fukuchi, S., Hamaguchi, K., Seike, M., Himeno, K., Sakata, T., and Yoshimatsu, H. 2004. Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp. Biol. Med. (Maywood), 229(6): 486-493.
21. Ghio, S., Scelsi, L., Latini, R., Masson, S., Eleuteri, E., Palvarini, M., et al. GISSI-HF investigators. 2010. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur. J. Heart Fail. 12(12): 1345-1353. doi:10.1093/eurjhf/hfq172.
22. GISSI-Prevenzione Investigators. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI- Prevenzione trial. Lancet, 354 (9177): 447-455. doi:10.1016/S0140-6736(99)07072-5.
23. Goldberg, I.J., Eckel, R.H., and Abumrad, N.A. 2009. Regulation of fatty acid uptake into tissues: lipoprotein lipase - and CD36-mediated pathways. J. Lipid Res. 50(Suppl.): S86-S90. doi:10. 1194/jlr.R800085-JLR200.
24. Igarashi, M., Ma, K., Chang, L., Bell, J.M., and Rapoport, S.I. 2008. Rat heart cannot synthesize docosahexaenoic acid from circulating a-linolenic acid because it lacks elongase-2. J. Lipid Res. 49(8): 1735-1745. doi:10.1194/jlr.M800093-JLR200.
25. Kowey, P.R., Reiffel, J.A., Ellenbogen, K.A., Naccarelli, G.V., and Pratt, C.M. 2010. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA, 304(21): 2363-2372. doi:10.1001/jama.2010.1735.
26. Leyva, D.R., Zahradka, P., Ramjiawan, B., Guzman, R., Aliani, M., and Pierce, G.N. 2011. The effect of dietary flaxseed on mproving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. Contemp. Clin. Trials, 32(5): 724-730. doi:10. 1016/j.cct.2011.05.005.
27. Lionetti, V., Linke, A., Chandler, M.P., Young, M.E., Penn, M.S., Gupte, S., et al. 2005. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc. Res. 66(3): 454-461.doi:10.1016/j.cardiores.2005.02.004.
28. Loch, D., Hoey, A., Morisseau, C., Hammock, B.O., and Brown, L. 2007. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 47(1): 87-98.
29. Lommi, J., Kupari, M., Koskinen, P., Naveri, H., Leinonen, H., Pulkki, K., and Härkönen, M. 1996. Blood ketone bodies in congestive heart failure. J. Am. Coll. Cardiol. 28(3): 665-672. doi:10.1016/0735-1097(96)00214-8.
30. Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., et al. GISSI-Prevenzione Investigators. 2002. Early protection against sudden death by n-3 polyunsaturated fatty acidsafter myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation, 105(16): 1897-1903. doi:10.1161/01.CIR.0000014682.14181.F2.
31. Mensink, G.B., Thamm, M., and Haas, K. 1999. Die Ernährung in Deutschland 1998 [Nutrition in Germany 1998]. Gesundheitswesen, 61(Spec. No.): S200-S206.
32. Meves, H. 2008. Arachidonic acid and ion channels: an update. Br. J. Pharmacol. 155(1): 4-16. doi:10.1038/bjp.2008.216.
33. Michaud, A.L., Diau, G.Y., Abril, R., and Brenna, J.T. 2002. Double bond localization in minor homoallylic fatty acid methyl esters using acetonitrile chemical ionization tandem mass spectrometry. Anal. Biochem. 307(2): 348-360. doi:10.1016/S0003-2697(02)00037-4.
34. Moertl, D., Hammer, A., Steiner, S., Hutuleac, R., Vonbank, K., and Berger, R. 2011. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am. Heart J. 161(5): 915.e1-915.e9. doi:10.1016/j.ahj.2011.02.011.
35. Montanaro, M.A., Gonzalez, M.S., Bernasconi, A.M., and Brenner, R.R. 2007. Role of liver X receptor, insulin and peroxisome proliferator activated receptor alpha on in vivo desaturase modulation of unsaturated fatty acid biosynthesis. Lipids, 42(3): 197-210. doi:10.1007/s11745-006-3006-4.
36. Nodari, S., Triggiani, M., Campia, U., Manerba, A., Milesi, G., Cesana, B.M., et al. 2011. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 57(7): 870-879. doi:10.1016/j.jacc.2010.11.017.
37. Noma, K., Brandle, M., Rupp, H., and Jacob, R. 1990. Left ventricular performance in rats with chronic cardiac overload due to arterio-venous shunt. Heart Vessels, 5(2): 65-70. doi:10.1007/BF02058319.
38. Oe, H., Hozumi, T., Murata, E., Matsuura, H., Negishi, K., Matsumura, Y., et al. 2008. Arachidonic acid and docosahexaenoic acid supplementation increases coronary flow velocity reserve in Japanese elderly individuals. Heart, 94(3): 316-321. doi:10.1136/hrt.2006.113159.
39. Ogata, T., Miyauchi, T., Sakai, S., Takanashi, M., Irukayama-Tomobe, Y., and Yamaguchi, I. 2004. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. 43(8): 1481-1488. doi:10.1016/j.jacc.2003.11.043.
40. Oh, D.Y., Talukdar, S., Bae, E.J., Imamura, T., Morinaga, H., Fan, W., et al. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell, 142(5): 687-698. doi:10.1016/j.cell.2010.07.041.
41. Ohkubo, T., Jacob, R., and Rupp, H. 1992. Swimming changes vascular fatty acid composition and prostanoid generation of rats. Am. J. Physiol. 262(3): R464-R471.
42. Pawlosky, R.J., Hibbeln, J.R., Novotny, J.A., and Salem, N., Jr. 2001. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J. Lipid Res. 42(8): 1257-1265.
43. Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., et al. OMEGA Study Group. 2010. OMEGA, a andomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy aftermyocardial infarction. Circulation, 122(21): 2152-2159. doi:10.1161/CIRCULATIONAHA.110.948562.
44. Rhaleb, N.E., Peng, H., Alfie, M.E., Shesely, E.G., and Carretero, O. A. 1999. Effect of ACE inhibitor on DOCA-salt - and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role? Hypertension, 33(1): 329-334.
45. Rodriguez-Leyva, D., Dupasquier, C.M., McCullough, R., and Pierce, G.N. 2010. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can. J. Cardiol. 26(9): 489-496. doi:10.1016/S0828-282X(10)70455-4.
46. Rupp, H., and Maisch, B. 1999. Radiotelemetric characterization of overweight-associated rises in blood pressure and heart rate. Am. J. Physiol. 277(4): H1540-H1545.
47. Rupp, H., and Vetter, R. 2000. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br. J. Pharmacol. 131(8): 1748-1756. doi:10.1038/sj.bjp.0703741.
48. Rupp, H., Wahl, R., and Hansen, M. 1992. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. J. Appl. Physiol. 72(1): 352-360.
49. Rupp, H., Elimban, V., and Dhalla, N.S. 1994. Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering nterventions. Mol. Cell. Biochem. 132(1): 69-80. doi:10.1007/BF00925676.
50. Rupp, H., Wahl, R., Maisch, B., and Hansen, M. 2002. Characterization of sucrose-induced changes in cardiac phenotype. Pflugers Arch. 445(1): 32-39. doi:10.1007/s00424-002-0905-y.
51. Rupp, H., Wagner, D., Rupp, T., Schulte, L.M., and Maisch, B. 2004. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz, 29(7): 673-685. doi:10.1007/s00059-004-2602-4.
52. Rupp, H., Rupp, T.P., and Maisch, B. 2005. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure? Cardiovasc. Res. 66 (3): 423-426. doi:10.1016/j.cardiores.2005.03.023.
53. Rupp, H., Rupp, T.P., Wagner, D., Alter, P., and Maisch, B. 2006.Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level". Herz, 31(Suppl. 3): 30-49.
54. Rupp, H., Rupp, T.P., Alter, P., and Maisch, B. 2010. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart, 96(8): 595-598. doi:10.1136/hrt.2009.176560.
55. Rupp, H., Rupp, T.P., Alter, P., and Maisch, B. 2011. Failure of omega-3 fatty acids in atrial fibrillation? No deficiency of highly unsaturated fatty acids in the absence of heart failure. Europace, 13 (9): 1357, author reply 1357-1358. doi:10.1093/europace/eur149.
56. Schupp, M., Kintscher, U., Fielitz, J., Thomas, J., Pregla, R., Hetzer, R., et al. 2006. Cardiac PPARalpha expression in patients with dilated cardiomyopathy. Eur. J. Heart Fail. 8(3): 290-294. doi:10. 1016/j.ejheart.2005.09.003.
57. Shah, A., and Shannon, R.P. 2003. Insulin resistance in dilated cardiomyopathy. Rev. Cardiovasc. Med. 4(Suppl. 6): S50-S57.
58. Signorello, M.G., Pascale, R., and Leoncini, G. 2002. Effect of homocysteine on arachidonic acid release in human platelets. Eur. J. Clin. Invest. 32(4): 279-284. doi:10.1046/j.1365-2362.2002.00971.x.
59. Skorin, C., Necochea, C., Johow, V., Soto, U., Grau, A.M., Bremer, J., and Leighton, F. 1992. Peroxisomal fatty acid oxidation and inhibitors of the mitochondrial carnitine palmitoyltransferase I in isolated rat hepatocytes. Biochem. J. 281(2): 561-567.
60. Stanley, W.C., Recchia, F.A., and Lopaschuk, G.D. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85(3): 1093-1129. doi:10.1152/physrev.00006.2004.1
61. Task Force of the European Society of Cardiology and the NorthAmerican Society of Pacing and Electrophysiology. 1996. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation, 93(5): 1043-1065. doi:10. 1161/01.CIR.93.5.1043.
62. Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., et al. Gissi-HF Investigators. 2008. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet, 372(9645): 1223-1230. doi:10.1016/S0140-6736(08)61239-8.
63. Turcani, M., and Rupp, H. 1997. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation, 96(10): 3681-3686.
64. Vessby, B., Gustafsson, I.B., Tengblad, S., Boberg, M., and Andersson, A. 2002. Desaturation and elongation of Fatty acids and insulin action. Ann. N. Y. Acad. Sci. 967(1): 183-195. doi:10.1111/j.1749-6632.2002.tb04275.x.
65. Voss, A., Reinhart, M., Sankarappa, S., and Sprecher, H. 1991. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J. Biol. Chem. 266(30): 19995-20000.
66. Wang, Y., Botolin, D., Christian, B., Busik, J., Xu, J., and Jump, D.B. 2005. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J. Lipid Res. 46(4): 706-715. doi:10.1194/jlr.M400335-JLR200.
67. Witteles, R.M., Tang, W.H., Jamali, A.H., Chu, J.W., Reaven, G.M., and Fowler, M.B. 2004. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J. Am. Coll. Cardiol. 44 (1): 78-81. doi:10.1016/j.jacc.2004.03.037.
68. Xiao, Y.F., Sigg, D.C., and Leaf, A. 2005. The antiarrhythmic effectof n-3 polyunsaturated fatty acids: modulation of cardiac ion channels as a potential mechanism. J. Membr. Biol. 206(2): 141-154. doi:10.1007/s00232-005-0786-z.
69. Young, J.B., Daly, P.A., Uemura, K., and Chaouloff, F. 1994. Effects of chronic lard feeding on sympathetic nervous system activity inthe rat. Am. J. Physiol. 267(5): R1320-R1328.